08:46 AM EDT, 07/11/2024 (MT Newswires) -- Abeona Therapeutics ( ABEO ) said Thursday it entered into an exclusive agreement with Beacon Therapeutics to evaluate its patented AAV204 capsid to potentially develop and market gene therapies for specific ophthalmic conditions.

Under the deal, Beacon Therapeutics has secured a 12-month evaluation period for AAV204 capsid for select ophthalmology indications and holds an option to obtain a global, non-exclusive license for up to five gene or disease target applications.

The company said Beacon could also use AAV204 for up to four additional nominated gene or disease targets.

Abeona will receive an upfront payment when Beacon exercises its licensing option.

Milestone payments linked to development, regulatory approvals and sales achievements, along with royalties on global net sales, are also part of the agreement, the company added.

Price: 4.9647, Change: -0.03, Percent Change: -0.51